CA2837207A1 - Nouveaux modulateurs du systeme immunitaire - Google Patents
Nouveaux modulateurs du systeme immunitaire Download PDFInfo
- Publication number
- CA2837207A1 CA2837207A1 CA2837207A CA2837207A CA2837207A1 CA 2837207 A1 CA2837207 A1 CA 2837207A1 CA 2837207 A CA2837207 A CA 2837207A CA 2837207 A CA2837207 A CA 2837207A CA 2837207 A1 CA2837207 A1 CA 2837207A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- heterocycle
- aryl
- cycloalkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161491966P | 2011-06-01 | 2011-06-01 | |
US61/491,966 | 2011-06-01 | ||
PCT/US2012/040425 WO2012167053A1 (fr) | 2011-06-01 | 2012-06-01 | Nouveaux modulateurs du système immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2837207A1 true CA2837207A1 (fr) | 2012-12-06 |
Family
ID=47259890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2837207A Abandoned CA2837207A1 (fr) | 2011-06-01 | 2012-06-01 | Nouveaux modulateurs du systeme immunitaire |
Country Status (6)
Country | Link |
---|---|
US (1) | US9353115B2 (fr) |
EP (1) | EP2713737B1 (fr) |
AU (1) | AU2012262021B2 (fr) |
CA (1) | CA2837207A1 (fr) |
ES (1) | ES2583877T3 (fr) |
WO (1) | WO2012167053A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE13857477T2 (hu) * | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Új vegyületek |
EP2953950B1 (fr) | 2013-02-11 | 2021-01-13 | The Regents of The University of California | Compositions et méthodes de traitement de maladies neurodégénératives |
HRP20220759T1 (hr) * | 2014-02-11 | 2022-09-02 | Mitokinin, Inc. | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
US11180474B2 (en) | 2016-07-30 | 2021-11-23 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
ES2902504T3 (es) | 2016-09-09 | 2022-03-28 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con piridilo |
CN108069960A (zh) * | 2016-11-15 | 2018-05-25 | 江苏豪森药业集团有限公司 | 利奥西呱中间体的制备方法 |
KR20200019228A (ko) * | 2017-06-21 | 2020-02-21 | 미토키닌, 인크. | 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법 |
WO2019028301A1 (fr) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | Composés d'indole substitués par [1,2,4]triazolo[4,3-a] pyridinyle |
US11447466B2 (en) | 2017-08-04 | 2022-09-20 | Bristol-Myers Squibb Company | Substituted indole compounds useful as inhibitors of TLR7/8/9 |
AU2018364807B2 (en) * | 2017-11-08 | 2022-05-19 | Council Of Scientific & Industrial Research | Purine based compounds as toll-like receptor 9 antagonist |
EP3710440B1 (fr) | 2017-11-14 | 2023-04-05 | Bristol-Myers Squibb Company | Composés d'indole substitués |
CA3085817A1 (fr) | 2017-12-18 | 2019-06-27 | Bristol-Myers Squibb Company | Composes de 4-azaindole |
WO2019126113A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Composés d'indole substitués utiles en tant qu'inhibiteurs de tlr |
EA202091483A1 (ru) | 2017-12-19 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr |
EP3728253B1 (fr) | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | Composés de 6-azaindole |
SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
EA202091479A1 (ru) | 2017-12-20 | 2020-11-24 | Бристол-Маерс Сквибб Компани | Арил- и гетероарилзамещенные индольные соединения |
CN111491929B (zh) | 2017-12-20 | 2023-11-28 | 百时美施贵宝公司 | 可用作tlr抑制剂的氨基吲哚化合物 |
TW202043234A (zh) | 2019-01-24 | 2020-12-01 | 美商普羅米修斯生物科學股份有限公司 | Gpr35調節劑 |
US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
CA3226162A1 (fr) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Composes aryle et compositions pharmaceutiques modulant l'ikzf2 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
JPS60260579A (ja) * | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
IL86007A0 (en) | 1987-04-09 | 1988-09-30 | Wellcome Found | 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
BR9407799A (pt) * | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
FI951367A (fi) * | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2194761C (fr) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Oligonucleotides immunomodulateurs |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
AR006928A1 (es) | 1996-05-01 | 1999-09-29 | Pioneer Hi Bred Int | Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas. |
WO1998037919A1 (fr) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES |
ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
JP2002514083A (ja) | 1997-05-07 | 2002-05-14 | シェーリング コーポレイション | ヒトToll様レセプタータンパク質、関連する試薬および方法 |
EP1003531B1 (fr) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Procedes de preparation de constructions d'acides nucleiques |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
MXPA02003059A (es) | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador. |
EA200200424A1 (ru) * | 1999-09-30 | 2002-12-26 | Ньюроджен Корпорейшн | Некоторые гетероциклы, замещенные алкилендиамином |
AU3540101A (en) * | 2000-01-07 | 2001-07-16 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
AU6488901A (en) | 2000-05-25 | 2001-12-03 | Schering Corp | Human receptor proteins; related reagents and methods |
SG177000A1 (en) | 2001-08-17 | 2012-01-30 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
JP2005506350A (ja) * | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
US20050227933A1 (en) * | 2001-11-29 | 2005-10-13 | Benkovic Stephen J | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
MX2011008500A (es) | 2009-02-11 | 2011-09-26 | Univ California | Moduladores del receptor tipo toll y tratamiento de enfermedades. |
-
2012
- 2012-06-01 AU AU2012262021A patent/AU2012262021B2/en not_active Ceased
- 2012-06-01 ES ES12793946.0T patent/ES2583877T3/es active Active
- 2012-06-01 EP EP12793946.0A patent/EP2713737B1/fr active Active
- 2012-06-01 WO PCT/US2012/040425 patent/WO2012167053A1/fr active Application Filing
- 2012-06-01 US US14/122,435 patent/US9353115B2/en active Active
- 2012-06-01 CA CA2837207A patent/CA2837207A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2583877T3 (es) | 2016-09-22 |
AU2012262021B2 (en) | 2016-07-28 |
EP2713737A4 (fr) | 2014-11-26 |
EP2713737A1 (fr) | 2014-04-09 |
WO2012167053A1 (fr) | 2012-12-06 |
EP2713737B1 (fr) | 2016-04-20 |
US20140107115A1 (en) | 2014-04-17 |
US9353115B2 (en) | 2016-05-31 |
AU2012262021A1 (en) | 2014-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012262021B2 (en) | Novel immune system modulators | |
US10117875B2 (en) | Immune system modulators | |
EP2763677B1 (fr) | Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline | |
US20170275287A1 (en) | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof | |
KR20080108353A (ko) | 단백질 키나제 억제제로서의 화합물 및 조성물 | |
JP2005516053A (ja) | 縮合複素環式化合物 | |
RU2198888C2 (ru) | 3-замещенные производные 3,4,5,6,7,8-гексагидропиридо[4',3':4,5]-тиено[2,3-d]пиримидина | |
CA3097403A1 (fr) | Inhibiteurs de stat3 | |
CA2954231A1 (fr) | Derives de quinolizinone utilises comme inhibiteurs de pi3k | |
KR102264189B1 (ko) | Pi3k 억제제인 피라졸로피리미딘 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20191105 |